IL1B and metabolic dysfunction-associated steatotic liver disease: In C57BL/6J mice with T2DM and NAFLD induced by STZ and a high-fat diet, empagliflozin reduces the hepatic amount of M1 pro-inflammatory macrophages and induces autophagy in macrophages via activating the AMPK/mammalian target of the rapamycin (mTOR) signaling pathway and inhibiting the IL-17/IL-23 axis (which includes IL-1β, STAT3, or IL-6, among others), contributing to the amelioration of NAFLD [199].